WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience The New Axio Examiner
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, February 23, 2005, 25(8):2102-2107; doi:10.1523/JNEUROSCI.5059-04.2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guigoni, C.
Right arrow Articles by Bezard, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guigoni, C.
Right arrow Articles by Bezard, E.

 Previous Article  |  Next Article 

BRIEF COMMUNICATION
Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia

Céline Guigoni,1 Qin Li,3 Incarnation Aubert,2 Sandra Dovero,1 Bernard H. Bioulac,1 Bertrand Bloch,2 Alan R. Crossman,4 Christian E. Gross,1 and Erwan Bezard1

1Basal Gang, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5543, and 2CNRS UMR 5541, Université Victor Segalen-Bordeaux 2, 33076 Bordeaux Cedex, France, 3Laboratory Animal Research Center, China Agricultural University, Beijing 100101, China, and 4School of Biological Sciences, University of Manchester, Manchester M13 9PT, United Kingdom

Dyskinesia represents a debilitating complication of L-3,4-dihydroxyphenylalanine (L-dopa) therapy for Parkinson's disease. Such motor manifestations are attributed to pathological activity in the motor parts of basal ganglia. However, because consistent funneling of information takes place between the sensorimotor, limbic, and associative basal ganglia domains, we hypothesized that nonmotor domains play a role in these manifestations. Here we report the changes in 2-deoxyglucose (2-DG) accumulation in the sensorimotor, limbic, and associative domains of basal ganglia and thalamic nuclei of four groups of nonhuman primates: normal, parkinsonian, parkinsonian chronically treated with L-dopa without exhibiting dyskinesia, and parkinsonian chronically treated with L-dopa and exhibiting overt dyskinesia. Although nondyskinetic animals display a rather normalized metabolic activity, dyskinetic animals are distinguished by significant changes in 2-DG accumulation in limbic- and associative-related structures and not simply in sensorimotor-related ones, suggesting that dyskinesia is linked to a pathological processing of limbic and cognitive information. We propose that these metabolic changes reflect the underlying neural mechanisms of not simply motor dyskinesias but also affective, motivational, and cognitive disorders associated with long-term exposure to L-dopa.

Key words: 2-deoxyglucose; globus pallidus pars externalis; subthalamic nucleus; mediodorsal nucleus; nucleus stria terminalis; basal ganglia


Received July 20, 2004; revised January 12, 2005; accepted January 15, 2005.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
S. J. Gold, C. V. Hoang, B. W. Potts, G. Porras, E. Pioli, K. W. Kim, A. Nadjar, C. Qin, G. J. LaHoste, Q. Li, et al.
RGS9 2 Negatively Modulates L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease
J. Neurosci., December 26, 2007; 27(52): 14338 - 14348.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. H. Evans, A. D. Lawrence, J. Potts, S. Appel, and A. J. Lees
Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease
Neurology, November 22, 2005; 65(10): 1570 - 1574.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-